111 related articles for article (PubMed ID: 18854802)
1. [Treatment of hyperandrogenism and hyperinsulinemia in PCOS patients with essential amino acids. A pilot clinical study].
Unfer V; Zacchè M; Serafini A; Redaelli A; Papaleo E
Minerva Ginecol; 2008 Oct; 60(5):363-8. PubMed ID: 18854802
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
3. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
4. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Garmes HM; Tambascia MA; Zantut-Wittmann DE
Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
[TBL] [Abstract][Full Text] [Related]
5. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
Kolodziejczyk B; Duleba AJ; Spaczynski RZ; Pawelczyk L
Fertil Steril; 2000 Jun; 73(6):1149-54. PubMed ID: 10856473
[TBL] [Abstract][Full Text] [Related]
6. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
7. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
9. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study.
Penna IA; Canella PR; Reis RM; Silva de Sá MF; Ferriani RA
Hum Reprod; 2005 Sep; 20(9):2396-401. PubMed ID: 16006454
[TBL] [Abstract][Full Text] [Related]
10. Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women.
Shi Y; Gao X; Sun X; Zhang P; Chen Z
Fertil Steril; 2008 Oct; 90(4):1139-43. PubMed ID: 17889857
[TBL] [Abstract][Full Text] [Related]
11. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS.
Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884
[TBL] [Abstract][Full Text] [Related]
12. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?
Vural B; Ozkan S; Bodur H
J Obstet Gynaecol Res; 2007 Apr; 33(2):166-73. PubMed ID: 17441890
[TBL] [Abstract][Full Text] [Related]
13. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study.
Romualdi D; Costantini B; Campagna G; Lanzone A; Guido M
Fertil Steril; 2008 Nov; 90(5):1826-33. PubMed ID: 18166189
[TBL] [Abstract][Full Text] [Related]
14. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
Otto-Buczkowska E; Jarosz-Chobot P; Deja G
Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide.
Ibáñez L; Potau N; Marcos MV; de Zegher F
J Clin Endocrinol Metab; 2000 Sep; 85(9):3251-5. PubMed ID: 10999817
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women.
Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY
Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512
[TBL] [Abstract][Full Text] [Related]
17. Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women.
Orio F; Giallauria F; Palomba S; Manguso F; Orio M; Tafuri D; Lombardi G; Carmina E; Colao A; Vigorito C
Clin Endocrinol (Oxf); 2008 Jun; 68(6):976-81. PubMed ID: 17980005
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2007 Mar; 12(1):30-5. PubMed ID: 17455042
[TBL] [Abstract][Full Text] [Related]
19. [Influence of weight and distribution of adipose tissue in functional hyperandrogenism].
Pasquali R; Vicennati V; Gambineri A
Contracept Fertil Sex; 1998 May; 26(5):372-5. PubMed ID: 9648381
[TBL] [Abstract][Full Text] [Related]
20. Polycystic ovarian syndrome: the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome.
Diamanti-Kandarakis E; Christakou C; Kandarakis H
Minerva Endocrinol; 2007 Mar; 32(1):35-47. PubMed ID: 17353865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]